Silexion Therapeutics Corp (NASDAQ:SLXN) Short Interest Update
by Danessa Lincoln · The Markets DailySilexion Therapeutics Corp (NASDAQ:SLXN – Get Free Report) was the recipient of a large growth in short interest in the month of September. As of September 15th, there was short interest totaling 238,617 shares, a growth of 1,545.5% from the August 31st total of 14,501 shares. Based on an average daily volume of 15,566,949 shares, the days-to-cover ratio is currently 0.0 days. Approximately 4.3% of the company’s stock are short sold.
Wall Street Analysts Forecast Growth
SLXN has been the subject of several recent research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Silexion Therapeutics in a research report on Friday, September 11th. Maxim Group lowered Silexion Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 29th. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold”.
Get Our Latest Analysis on Silexion Therapeutics
Silexion Therapeutics Trading Down 18.5%
Shares of SLXN opened at $0.26 on Friday. The stock has a market capitalization of $1.43 million, a price-to-earnings ratio of -0.01 and a beta of -0.36. Silexion Therapeutics has a 12 month low of $0.25 and a 12 month high of $42.60. The firm has a fifty day simple moving average of $0.98 and a 200 day simple moving average of $5.13.
Silexion Therapeutics (NASDAQ:SLXN – Get Free Report) last issued its quarterly earnings results on Saturday, August 15th. The company reported ($5.17) EPS for the quarter, topping the consensus estimate of ($21.20) by $16.03. As a group, research analysts predict that Silexion Therapeutics will post -4.7 earnings per share for the current fiscal year.
Silexion Therapeutics Company Profile
Silexion Therapeutics Ltd. is an Israel-based clinical-stage biotechnology company focused on developing RNA-based treatments for solid tumors driven by mutations in the KRAS gene. The company’s research is centered on gene-silencing technologies designed to inhibit KRAS, an important cancer-promoting protein that has historically been difficult to target with conventional therapies.
Silexion’s development programs include SIL-204, an investigational small interfering RNA (siRNA) therapy designed to target KRAS mutations, including KRAS G12D, a frequently observed mutation in pancreatic cancer.